CN116033940A - 激活内源性抗菌药物治疗sars-cov-2感染 - Google Patents

激活内源性抗菌药物治疗sars-cov-2感染 Download PDF

Info

Publication number
CN116033940A
CN116033940A CN202180033610.XA CN202180033610A CN116033940A CN 116033940 A CN116033940 A CN 116033940A CN 202180033610 A CN202180033610 A CN 202180033610A CN 116033940 A CN116033940 A CN 116033940A
Authority
CN
China
Prior art keywords
day
subject
hydroxyvitamin
days
level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180033610.XA
Other languages
English (en)
Chinese (zh)
Inventor
查理斯·W·比绍夫
斯蒂芬·A·斯特拉格内尔
阿赫塔尔·阿什法克
雷姆·伊拉曼·埃尔西迪希
科尔姆·纳尔蒂
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elgin Pharmaceutical Co ltd
Original Assignee
Elgin Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elgin Pharmaceutical Co ltd filed Critical Elgin Pharmaceutical Co ltd
Publication of CN116033940A publication Critical patent/CN116033940A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CN202180033610.XA 2020-04-06 2021-04-06 激活内源性抗菌药物治疗sars-cov-2感染 Pending CN116033940A (zh)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202063006034P 2020-04-06 2020-04-06
US63/006,034 2020-04-06
US202063006563P 2020-04-07 2020-04-07
US63/006,563 2020-04-07
US202063009155P 2020-04-13 2020-04-13
US63/009,155 2020-04-13
US202063012781P 2020-04-20 2020-04-20
US63/012,781 2020-04-20
US202063032714P 2020-05-31 2020-05-31
US63/032,714 2020-05-31
PCT/IB2021/000220 WO2021205225A1 (en) 2020-04-06 2021-04-06 25-hydroxyvitamin d for the treatment of sars-cov-2 infection

Publications (1)

Publication Number Publication Date
CN116033940A true CN116033940A (zh) 2023-04-28

Family

ID=75904967

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180033610.XA Pending CN116033940A (zh) 2020-04-06 2021-04-06 激活内源性抗菌药物治疗sars-cov-2感染

Country Status (8)

Country Link
US (2) US20210308151A1 (https=)
EP (1) EP4132477A1 (https=)
JP (1) JP2023520591A (https=)
KR (1) KR20220164539A (https=)
CN (1) CN116033940A (https=)
CA (1) CA3176559A1 (https=)
TW (1) TW202203936A (https=)
WO (1) WO2021205225A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116785295A (zh) * 2023-06-29 2023-09-22 吉林大学 雷特格韦在防治新型冠状病毒感染药物中的应用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2862462B2 (es) * 2020-04-06 2023-04-27 Servicio Andaluz De Salud Compuestos para la profilaxis y/o el tratamiento del sindrome de dificultad respiratoria aguda
CN120694962A (zh) * 2020-05-31 2025-09-26 艾尔金制药有限公司 硬胶囊剂型和其用途
WO2025094144A1 (en) 2023-11-02 2025-05-08 Eirgen Pharma Ltd. Controlling loss of kidney function

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106604733A (zh) * 2014-08-07 2017-04-26 欧普科爱尔兰环球控股有限公司 利用25‑羟基维生素d的辅助疗法
CN108883120A (zh) * 2016-03-28 2018-11-23 欧普科爱尔兰环球控股有限公司 维生素d治疗方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264223A (en) 1990-03-29 1993-11-23 Japan Elanco Company, Ltd. Hard capsule for pharmaceutical drugs and method for producing the same
US5431917A (en) 1992-10-08 1995-07-11 Japan Elanco Company, Ltd. Hard capsule for pharmaceutical drugs and method for producing the same
FR2757173A1 (fr) 1996-12-17 1998-06-19 Warner Lambert Co Compositions polymeres d'origine non-animale pour la formation de films
KR100379674B1 (ko) 2000-03-06 2003-04-10 주식회사 서흥캅셀 펙틴과 글리세린의 배합용액을 이용한 셀룰로오스 캅셀 및그의 제조방법
ES2593047T3 (es) * 2006-02-03 2016-12-05 Opko Renal, Llc Tratamiento de la insuficiencia y deficiencia de vitamina D con 25-hidroxivitamina D2 y 25-hidroxivitamina D3
US20080031957A1 (en) 2006-05-15 2008-02-07 Deluca Hector F Pulmonary delivery of 1alpha,25-dihydroxyvitamin D3 and co-administration of parathyroid hormone or calcitonin
FR2902092B1 (fr) 2006-06-07 2008-09-05 Sapelem Soc Par Actions Simpli Appareil de manutention de charge
KR20190028822A (ko) * 2007-04-25 2019-03-19 사이토크로마 인코포레이티드 비타민 ｄ 화합물과 밀랍성 담체를 포함하는 경구 조절성 방출 조성물
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
JP7603000B2 (ja) 2018-08-31 2024-12-19 オプコ アイルランド グローバル ホールディングス リミテッド ビタミンｄ小児用剤形、製造方法および使用方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106604733A (zh) * 2014-08-07 2017-04-26 欧普科爱尔兰环球控股有限公司 利用25‑羟基维生素d的辅助疗法
CN108883120A (zh) * 2016-03-28 2018-11-23 欧普科爱尔兰环球控股有限公司 维生素d治疗方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GRANT WB，等: "Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths", NUTRIENTS, vol. 12, no. 4, 2 April 2020 (2020-04-02), pages 9, XP055761340, DOI: 10.3390/nu12040988 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116785295A (zh) * 2023-06-29 2023-09-22 吉林大学 雷特格韦在防治新型冠状病毒感染药物中的应用

Also Published As

Publication number Publication date
CA3176559A1 (en) 2021-10-14
JP2023520591A (ja) 2023-05-17
KR20220164539A (ko) 2022-12-13
EP4132477A1 (en) 2023-02-15
WO2021205225A1 (en) 2021-10-14
US20210308151A1 (en) 2021-10-07
WO2021205225A8 (en) 2023-01-05
US20250144119A1 (en) 2025-05-08
TW202203936A (zh) 2022-02-01

Similar Documents

Publication Publication Date Title
CN116033940A (zh) 激活内源性抗菌药物治疗sars-cov-2感染
Hansdottir et al. Vitamin D effects on lung immunity and respiratory diseases
Dudgeon et al. Counteracting muscle wasting in HIV‐infected individuals
Armuzzi et al. Adalimumab in active ulcerative colitis: a “real-life” observational study
JP5563296B2 (ja) 二次性副甲状腺機能亢進症の治療及び予防方法
CN100349573C (zh) 用于亲脂性药物的制剂
Contreras-Bolívar et al. Vitamin D and COVID-19: where are we now?
Carrozzo et al. Oral mucosal injury caused by targeted cancer therapies
JPH05501408A (ja) 微粒子薬物組成物
JP2013541010A (ja) グラチラマーアセテートに対する臨床的な反応の予測可能なバイオマーカーとしてのサイトカインバイオマーカー
JP2017507655A (ja) ＴＡＴｋ−ＣＤＫＬ５融合タンパク質、組成物、製剤、及びそれらの使用
JP2017507655A5 (https=)
Miller et al. Oxandrolone treatment in adults with severe thermal injury
Balog et al. HIV wasting syndrome: treatment update
WO2021195119A1 (en) Methods of reducing the risk of, severity of, and treating coronavirus infections
CN120694962A (zh) 硬胶囊剂型和其用途
Wang et al. High intestinal isoleucine is a potential risk factor for food allergy by regulating the mTOR/AKT pathway in dendritic cells
EP4135705A1 (en) Eclitasertib for use in treating conditions involving systemic hyperinflammatory response
EP4225440A1 (en) Methods for delivering medium chain triglycerides with controlled pharmacokinetic, safety and tolerability profiles
JP2017533239A (ja) 不安定または吸収不良薬物の経口投与
EP4125858B1 (en) Nutritional composition comprising l-carnitine tartrate for use in treating or preventing a coronavirus infection in a mammal
US20260060974A1 (en) Therapeutic tyrosine kinase inhibitors for multiple sclerosis
US20250090512A1 (en) Dosage Regimen
EP4702980A1 (en) Isolithocholic acid for use in the prevention or treatment of inflammatory diseases of the respiratory system
El Hadad et al. Impact of Saccharomyces cerevisiae Probiotic on Influenza Vaccine Efficacy in Diabetic Rats: An Immunological Perspective

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination